Know Cancer

or
forgot password


Phase 3
10 Years
70 Years
Not Enrolling
Both
Lymphoma, Non-Hodgkin

Thank you

Trial Information


Inclusion Criteria:



- Histologically documented, aggressive and/or intermediate grade NHL, B-cell and
T-cell.

- In relapse after first-line conventional chemotherapy. Primary therapy should
include a doxorubicin-based regimen.

- Patients must have disease sensitive to induction chemotherapy, radiation therapy,
and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is
allowed.

- Patients must have accessible tumor for biopsy or excision.

- Cumulative total doxorubicin: <500 mg/m2

- Performance score 0-2

- No prior pelvic RT

- Patients with a prior malignancy are eligible if they were treated for cure and have
no evidence of active disease.

- Patients may not be taking immunosuppressive agents.

- Informed Consent; IRB approval

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

NCRR-M01RR00042-1694

NCT ID:

NCT00006434

Start Date:

Completion Date:

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Dendritic cells
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

University of Michigan Medical CenterAnn Arbor, Michigan  48104-0914